Novavax Inc (NVAX.O)

NVAX.O

About

Novavax, Inc. (Novavax), is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company’s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	2.03
Market Cap (Mil.):	$301.88
Shares Outstanding (Mil.):	152.46
Dividend:	--
Yield (%):	--

Financials

	NVAX.O	Industry	Sector
P/E (TTM):	--	54.65	35.85
EPS (TTM):	-0.22	--	--
ROI:	-41.44	0.83	18.76
ROE:	-47.21	1.79	19.57

Latest News about NVAX.O

Novavax vaccine meets mid-stage trial goal, shares rise

- Novavax Inc said its vaccine to treat a virus that causes respiratory tract infections met the main goal, of immunizing women of childbearing age, in a mid-stage trial.

02 Apr 2013

UPDATE 1-Novavax vaccine meets mid-stage trial goal, shares rise

* Respiratory tract infection vaccine immunizes women of childbearing age

02 Apr 2013

» More NVAX.O News

Competitors

	Price	Change
Novartis AG (NOVN.VX)	CHF72.40	+0.65
Merck & Co., Inc. (MRK.N)	$45.57	+0.36
Sanofi SA (SASY.PA)	€85.14	+0.83
AstraZeneca plc (AZN.L)	3,394.50p	+4.00
GlaxoSmithKline plc (GSK.L)	1,742.00p	+20.50

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - NOVAVAX, INC. (NVAX-O) Provider: Thomson Reuters Stock Report	$25.00 Buy
NOVAVAX INC (NVAX) 12-months forecast Provider: Pechala's Reports	$15.00 Buy
Novavax Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Novavax Inc Provider: S&P Capital IQ Quantitative Report	$69.00 Buy
ValuEngine Detailed Valuation Report for NVAX Provider: ValuEngine, Inc.	$127.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.